Changing the worldTime 2022-09-05 03:13:21
Web Name: Changing the world
Changing the world
UCLB is the commercialisation company of UCL. We bring to market truly world-leading, world-changing technologies and innovations that have a real and positive impact on people’s lives.
Find out moreFind your business managerForms and resources Find UCL innovations
First gene therapy for adults with severe Haemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe haemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).Read more News
Moving with the times
Senceive’s technology platform integrates sensors, interfacing/algorithms, wireless platforms, gateways, data backhaul, and data into a flexible, extendable wireless solution that enables precise and reliable monitoring for challenging applications, providing customers with repeatable, high-quality asset performance data.Read more case studies
We want you to have the best experience possible when using our website.
<<< Thank you for your visit >>>